欧洲基于共识的侵袭性皮肤鳞状细胞癌跨学科指南。第一部分：诊断和预防-2023年更新。
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
发表日期：2023 Jul 28
作者：
Alexander J Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, Veronique Bataille, Lars Bastholt, Brigitte Dreno, Reinhard Dummer, Maria Concetta Fargnoli, Ana Maria Forsea, Catherine A Harwood, Axel Hauschild, Christoph Hoeller, Lidija Kandolf-Sekulovic, Roland Kaufmann, Nicole Wj Kelleners-Smeets, Aimilios Lallas, Ulrike Leiter, Josep Malvehy, Veronique Del Marmol, David Moreno-Ramirez, Giovanni Pellacani, Ketty Peris, Philippe Saiag, Luca Tagliaferri, Myrto Trakatelli, Dimitrios Ioannides, Ricardo Vieira, Iris Zalaudek, Petr Arenberger, Alexander M M Eggermont, Martin Röcken, Jean-Jacques Grob, Paul Lorigan,
来源：
MEDICINE & SCIENCE IN SPORTS & EXERCISE
摘要：
肌肤浸润性鳞状细胞癌（cSCC）是白种人群中最常见的癌症之一，占所有表皮恶性肿瘤的20%。总体上，经过治疗后，cSCC的预后通常非常好，5年治愈率超过90%。尽管总体预后良好且死亡率相对较低，但由于cSCC的高发病率，导致的死亡人数较多。针对cSCC的更新指南是由欧洲皮肤肿瘤专业协会（EADO）、欧洲皮肤病论坛（EDF）、欧洲放射治疗与肿瘤学协会（ESTRO）、欧洲医学专家联合会（UEMS）、欧洲皮肤科与性病学学会（EADV）和欧洲癌症研究与治疗组织（EORTC）的跨学科专家合作组成，根据当前文献和专家共识来更新cSCC方面的建议。指南的第一部分涉及免疫功能正常和免疫功能抑制患者的分类、流行病学、诊断、风险分层、分期和预防的更新。版权所有©2023作者。由Elsevier有限公司出版。保留所有权利。
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.